Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.61 USD
-0.04 (-0.86%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.62 +0.01 (0.22%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth A Momentum D VGM
Vanda Pharmaceuticals (VNDA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.50 | $13.00 | $6.00 | 104.30% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Vanda Pharmaceuticals comes to $9.50. The forecasts range from a low of $6.00 to a high of $13.00. The average price target represents an increase of 104.3% from the last closing price of $4.65.
Analyst Price Targets (2 )
Broker Rating
Vanda Pharmaceuticals currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, one is Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | NA |
Buy | 0 | 0 | 0 | 0 | NA |
Hold | 1 | 1 | 1 | 0 | NA |
Sell | 0 | 0 | 0 | 0 | NA |
Strong Sell | 0 | 0 | 0 | 0 | NA |
ABR | 2.00 | 2.00 | 2.00 | 1.00 | NA |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/11/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 2 |
Average Target Price | $9.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.18 |
VNDA FAQs
Vanda Pharmaceuticals Inc. (VNDA) currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 2 brokerage firms.
The average price target for Vanda Pharmaceuticals Inc. (VNDA) is $9.50. The current on short-term price targets is based on 2 reports.
The forecasts for Vanda Pharmaceuticals Inc. (VNDA) range from a low of $6 to a high of $13. The average price target represents a increase of $106.07 from the last closing price of $4.61.
The current UPSIDE for Vanda Pharmaceuticals Inc. (VNDA) is 106.07%
Based on short-term price targets offered by two analysts, the average price target for Vanda Pharmaceuticals comes to $9.50. The forecasts range from a low of $6.00 to a high of $13.00. The average price target represents an increase of 104.3% from the last closing price of $4.65.